Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07779798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07779798 · ClinicalTrials.gov record · last posted 2026-08-21

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

Study acronym: TelOscope
StatusNot Yet Recruiting
PhasePhase 1
Started2026-08
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication cohorts'). Participants aged ≥18 years are planned to be enrolled. CBX-663 will initially be investigated on a fixed dosing schedule. CBX-663 will be administered intravenously (IV) on Cycle 1 Day 1 (C1D1) and then once weekly (QW) in 21-day cycles. Participants will continue treatment with CBX-663 until unacceptable toxicity, progressive disease, withdrawal of consent, or lack of clinical benefit.
Trial Details
NCT Number NCT07779798
Lead Sponsor Crossbow Therapeutics, Inc.
Conditions Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
Enrollment 120 participants
Start Date 2026-08
Primary Completion 2028-01 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-21